Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYSLTR1 | Q9Y271 | 3/20 | 0.49 |
| ▸ | CYSLTR2 | Q9NS75 | 2/20 | 0.49 |
| ▸ | ABCC1 | P33527 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | ABCC3 | O15438 | 1/20 | 0.46 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.46 |
| ▸ | ABCC5 | O15440 | 1/20 | 0.46 |
| ▸ | SLCO2B1 | O94956 | 1/20 | 0.46 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | ABCC2 | Q92887 | 1/20 | 0.46 |
| ▸ | SLCO1B3 | Q9NPD5 | 1/20 | 0.46 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.46 |
| ▸ | SLCO1B1 | Q9Y6L6 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Water SCHEMBL3202787 | 0.87 | CYSLTR1 (0.54) | CYSLTR1CYSLTR2ABCC1MEN1ABCC3 | |
| SCHEMBL5704980 | 0.78 | CYSLTR2 (0.51) | CYSLTR1CYSLTR2 | |
| SCHEMBL5493622 | 0.78 | CYSLTR1 (0.58) | CYSLTR1CYSLTR2ABCC1MEN1ABCC3 | |
| SCHEMBL3262566 | 0.76 | CYSLTR1 (0.46) | CYSLTR1CYSLTR2ABCC1MEN1ABCC3 | |
| SCHEMBL3262565 | 0.76 | CYSLTR1 (0.46) | CYSLTR1CYSLTR2ABCC1MEN1ABCC3 | |
| SCHEMBL5007865 | 0.75 | CYSLTR1 (0.49) | CYSLTR1CYSLTR2ABCC1MEN1ABCC3 | |
| SCHEMBL21812732 | 0.75 | CYSLTR1 (0.53) | CYSLTR1CYSLTR2ABCC1MEN1ABCC3 | |
| SCHEMBL21812796 | 0.75 | CYSLTR1 (0.54) | CYSLTR1CYSLTR2ABCC1MEN1ABCC3 | |
| SCHEMBL3355559 | 0.74 | CYSLTR1 (0.53) | CYSLTR1CYSLTR2MEN1ABCB11KMT2A | |
| SCHEMBL21812960 | 0.74 | CYSLTR1 (0.56) | CYSLTR1CYSLTR2ABCC1MEN1ABCC3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7829716-B2 | decyclization of {3-[(E)-2(7-chloro-2-quinolinyl)vinyl]phenyl}-4,5-dihydro-3H-benzo[c]thiepin-1-one by methylmagnesium halide with following conversion to montelukast | Synthon Pharmaceuticals, Inc. (US) | 2010-11-09 | — | — | US | disclosed |
| EP-1740545-B1 | PROCESS FOR MAKING MONTELUKAST AND INTERMEDIATES THEREFOR | SYNTHON BV (NL) | 2010-03-24 | — | — | EP | disclosed |
| EP-1740545-A1 | PROCESS FOR MAKING MONTELUKAST AND INTERMEDIATES THEREFOR | Synthon B.V. (NL) | 2007-01-10 | — | — | EP | disclosed |
| WO-2005105750-A1 | PROCESS FOR MAKING MONTELUKAST AND INTERMEDIATES THEREFOR | SYNTHON B.V. (NL) | 2005-11-10 | — | — | WO | disclosed |
| US-20050245568-A1 | Process for making montelukast and intermediates therefor | SYNTHON BV (NL) | 2005-11-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050245568-A1 | Process for making montelukast and intermediates therefor | CYP51A1, GPR17, CYP27A1 | CYSLTR1 9/4885CYSLTR2 15/4885ABCC1 3225/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.